52 related articles for article (PubMed ID: 20963947)
1. [Clinical significance of apolipoprotein B-48 (apoB-48) in chronic kidney disease patients].
Okubo M; Hanada H; Matsui M; Hidaka Y; Masuda D; Yamashita S
Rinsho Byori; 2010 Sep; 58(9):878-83. PubMed ID: 20963947
[TBL] [Abstract][Full Text] [Related]
2. [Clinical significance of apolipoprotein B-48 (apoB-48) in patients with thyroid disease].
Mugii S; Hanada H; Takeoka K; Hidaka Y; Masuda D; Ohama T; Toyama Y; Yamashita S
Rinsho Byori; 2009 Nov; 57(11):1058-63. PubMed ID: 20030174
[TBL] [Abstract][Full Text] [Related]
3. Oxidized low-density lipoprotein biomarkers in patients with end-stage renal failure: acute effects of hemodialysis.
Bossola M; Tazza L; Merki E; Giungi S; Luciani G; Miller ER; Lin EB; Tortorelli A; Tsimikas S
Blood Purif; 2007; 25(5-6):457-65. PubMed ID: 18075247
[TBL] [Abstract][Full Text] [Related]
4. Establishment of chemiluminescence enzyme immunoassay for apolipoprotein B-48 and its clinical applications for evaluation of impaired chylomicron remnant metabolism.
Hanada H; Mugii S; Okubo M; Maeda I; Kuwayama K; Hidaka Y; Kitazume-Taneike R; Yamashita T; Kawase R; Nakaoka H; Inagaki M; Yuasa-Kawase M; Nakatani K; Tsubakio-Yamamoto K; Masuda D; Ohama T; Matsuyama A; Ishigami M; Nishida M; Komuro I; Yamashita S
Clin Chim Acta; 2012 Jan; 413(1-2):160-5. PubMed ID: 21958700
[TBL] [Abstract][Full Text] [Related]
5. Serum apolipoprotein B-48 concentration is associated with a reduced estimated glomerular filtration rate and increased proteinuria.
Okubo M; Hanada H; Matsui M; Hidaka Y; Masuda D; Sakata Y; Yamashita S
J Atheroscler Thromb; 2014; 21(9):974-82. PubMed ID: 24882621
[TBL] [Abstract][Full Text] [Related]
6. Temporal discrepancies in the association between the apoB/apoA-I ratio and mortality in incident dialysis patients.
Chmielewski M; Carrero JJ; Qureshi AR; Axelsson J; Heimbürger O; Berglund L; Bárány P; Rutkowski B; Lindholm B; Stenvinkel P
J Intern Med; 2009 Jun; 265(6):708-16. PubMed ID: 19298498
[TBL] [Abstract][Full Text] [Related]
7. Lipid and apolipoproteins (ApoAI, ApoB, Apo CIII, ApoE) disturbance in hemodialysis (HD) and renal transplant (Tx) patients.
Janicki K; Solski J; Janicka L; Kimak E; Bednarek-Skublewska A; Stettner S; Molas G
Ann Univ Mariae Curie Sklodowska Med; 2004; 59(1):459-66. PubMed ID: 16146031
[TBL] [Abstract][Full Text] [Related]
8. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease - possible candidates for paradoxical epidemiology?
Busch M; Fleck C; Wolf G; Stein G
Amino Acids; 2006 May; 30(3):225-32. PubMed ID: 16680555
[TBL] [Abstract][Full Text] [Related]
9. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
Siu YP; Leung KT; Tong MK; Kwan TH
Am J Kidney Dis; 2006 Jan; 47(1):51-9. PubMed ID: 16377385
[TBL] [Abstract][Full Text] [Related]
10. Body mass index and cardiovascular risk factors and biomarkers in hemodialysis patients.
Bossola M; Giungi S; Panocchia N; Vulpio C; Luciani G; Tazza L
J Nephrol; 2008; 21(2):197-204. PubMed ID: 18446714
[TBL] [Abstract][Full Text] [Related]
11. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ
Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863
[TBL] [Abstract][Full Text] [Related]
12. [Fundamental evaluation of apolipoprotein B-48 by chemiluminescence enzyme immunoassay--identification of apolipoprotein B-48 with immunoblotting].
Sato I; Fujioka Y; Hayashi F; Mukai M; Kawano S; Ishikawa Y; Yamashita S; Kumagai S
Rinsho Byori; 2007 Jun; 55(6):528-34. PubMed ID: 17657985
[TBL] [Abstract][Full Text] [Related]
13. Oxalic Acid as a uremic toxin.
Mydlík M; Derzsiová K
J Ren Nutr; 2008 Jan; 18(1):33-9. PubMed ID: 18089441
[TBL] [Abstract][Full Text] [Related]
14. The association between serum apolipoprotein A-I and apolipoprotein B and the severity of angiographical coronary artery disease.
Khadem-Ansari MH; Rasmi Y; Rahimi-Pour A; Jafarzadeh M
Singapore Med J; 2009 Jun; 50(6):610-3. PubMed ID: 19551315
[TBL] [Abstract][Full Text] [Related]
15. Circulating levels of adhesion molecules in chronic kidney disease correlate with the stage of renal disease and with C-reactive protein.
Vaccaro F; Mulè G; Cottone S; Soresi M; Giannitrapani L; Vadalà A; Sparacino V; Calabrese S; Picone FP; Montalto G; Cerasola G
Arch Med Res; 2007 Jul; 38(5):534-8. PubMed ID: 17560459
[TBL] [Abstract][Full Text] [Related]
16. Increased serum concentrations of pro-gastrin-releasing peptide in patients with renal dysfunction.
Kamata K; Uchida M; Takeuchi Y; Takahashi E; Sato N; Miyake Y; Okubo M; Kodama T; Yamaguchi K
Nephrol Dial Transplant; 1996 Jul; 11(7):1267-70. PubMed ID: 8672021
[TBL] [Abstract][Full Text] [Related]
17. Plasma reduced homocysteine and other aminothiol concentrations in patients with CKD.
Sjöberg B; Anderstam B; Suliman M; Alvestrand A
Am J Kidney Dis; 2006 Jan; 47(1):60-71. PubMed ID: 16377386
[TBL] [Abstract][Full Text] [Related]
18. Prostaglandins and hypertension in chronic renal diseases.
Hornych A; Bedrossian J; Bariety J; Menard J; Corvol P; Safar M; Fontaliran F; Milliez P
Clin Nephrol; 1975 Oct; 4(4):144-51. PubMed ID: 1104234
[TBL] [Abstract][Full Text] [Related]
19. Quantification of apolipoprotein A-I and B messenger RNA in heavy drinkers according to liver disease.
Mathurin P; Vidaud D; Vidaud M; Bedossa P; Paradis V; Ratziu V; Chaput JC; Poynard T
Hepatology; 1996 Jan; 23(1):44-51. PubMed ID: 8550047
[TBL] [Abstract][Full Text] [Related]
20. [Blood lipids in renal amyloidosis].
Srinivas KV; Neverov NI; Kolonduk NV; Tambovtseva EV; Kozlova RI
Urol Nefrol (Mosk); 1993; (1):28-31. PubMed ID: 7941122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
